AR092172A1 - Derivados de piridina, su preparacion y su uso en el tratamiento de enfermedades mediadas por la inhibicion de la cisteina-proteasa catepsina s o l - Google Patents

Derivados de piridina, su preparacion y su uso en el tratamiento de enfermedades mediadas por la inhibicion de la cisteina-proteasa catepsina s o l

Info

Publication number
AR092172A1
AR092172A1 ARP130102939A ARP130102939A AR092172A1 AR 092172 A1 AR092172 A1 AR 092172A1 AR P130102939 A ARP130102939 A AR P130102939A AR P130102939 A ARP130102939 A AR P130102939A AR 092172 A1 AR092172 A1 AR 092172A1
Authority
AR
Argentina
Prior art keywords
treatment
catepsina
cistein
proteasa
piridine
Prior art date
Application number
ARP130102939A
Other languages
English (en)
Inventor
Anselm Lilli
Banner David
Haap Wolfgang
Kuhn Bernd
Luebbers Thomas
Peters Jens
Uwe-Spinnler Beat
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46851300&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR092172(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR092172A1 publication Critical patent/AR092172A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Este compuesto puede utilizarse como medicamento para el tratamiento de enfermedades metabólicas. Reivindicación 1: Un compuesto de la fórmula (1) en la que: A¹ es -S- o -S(O)₂-; A² es nitrógeno o -(CH)-; R¹ es halógeno o haloalquilo; R² es hidrógeno o halógeno; R³ es hidrógeno, halógeno, haloalquilo, pirazolilo, [1,2,3]-triazolilo o [1,2,4]-triazolilo; R⁴ y R⁶ se eligen con preferencia entre hidrógeno, alquilo, haloalquilo y halofenilo; y R⁵ es hidrógeno, halógeno, haloalquilo, alcoxi, haloalcoxi, alquilpiridinilo, halopiridinilo o alquilpirazolilo; o una sal farmacéuticamente aceptable del mismo.
ARP130102939A 2012-08-21 2013-08-20 Derivados de piridina, su preparacion y su uso en el tratamiento de enfermedades mediadas por la inhibicion de la cisteina-proteasa catepsina s o l AR092172A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12181247 2012-08-21

Publications (1)

Publication Number Publication Date
AR092172A1 true AR092172A1 (es) 2015-03-25

Family

ID=46851300

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102939A AR092172A1 (es) 2012-08-21 2013-08-20 Derivados de piridina, su preparacion y su uso en el tratamiento de enfermedades mediadas por la inhibicion de la cisteina-proteasa catepsina s o l

Country Status (24)

Country Link
US (1) US9409882B2 (es)
EP (1) EP2888244A1 (es)
JP (1) JP2015530997A (es)
KR (1) KR20150044947A (es)
CN (1) CN104583198A (es)
AR (1) AR092172A1 (es)
AU (1) AU2013305102A1 (es)
BR (1) BR112015003217A2 (es)
CA (1) CA2879796A1 (es)
CL (1) CL2015000354A1 (es)
CO (1) CO7200259A2 (es)
CR (1) CR20150073A (es)
EA (1) EA025166B1 (es)
HK (1) HK1206716A1 (es)
IL (1) IL237128A0 (es)
IN (1) IN2015DN00962A (es)
MA (1) MA37893A1 (es)
MX (1) MX2015002026A (es)
PE (1) PE20150995A1 (es)
PH (1) PH12015500262A1 (es)
SG (1) SG11201500900YA (es)
TW (1) TW201412728A (es)
WO (1) WO2014029722A1 (es)
ZA (1) ZA201500625B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018009638A (es) * 2016-02-26 2018-09-11 Hoffmann La Roche Derivados novedosos de pirrolidina.
WO2018139438A1 (ja) 2017-01-24 2018-08-02 アステラス製薬株式会社 フェニルジフルオロメチル置換プロリンアミド化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903610D0 (sv) 1999-10-06 1999-10-06 Astra Ab Novel compounds II
RU2007129779A (ru) 2005-01-06 2009-02-20 Астразенека Аб (Se) Новые соединения пиридина
AU2007209051A1 (en) 2006-01-24 2007-08-02 Actelion Pharmaceuticals Ltd Novel pyridine derivatives
JP5497633B2 (ja) * 2007-05-09 2014-05-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒのモジュレーター
AU2008328956A1 (en) 2007-11-30 2009-06-04 F. Hoffmann-La Roche Ag Pyridine compounds
CA2714665A1 (en) 2008-03-06 2009-09-11 Actelion Pharmaceuticals Ltd Pyridine compounds
NZ595073A (en) * 2009-04-20 2012-11-30 Hoffmann La Roche Proline derivatives as cathepsin inhibitors
US8394834B2 (en) * 2009-08-25 2013-03-12 Hoffman-La Roche Inc. Pyrrolidines as NK3 receptor antagonists
WO2013049559A1 (en) 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Pyridine derivatives

Also Published As

Publication number Publication date
BR112015003217A2 (pt) 2017-07-04
KR20150044947A (ko) 2015-04-27
WO2014029722A1 (en) 2014-02-27
HK1206716A1 (en) 2016-01-15
MX2015002026A (es) 2015-06-05
CA2879796A1 (en) 2014-02-27
CO7200259A2 (es) 2015-02-27
TW201412728A (zh) 2014-04-01
US20150307472A1 (en) 2015-10-29
PH12015500262A1 (en) 2015-03-30
EA025166B1 (ru) 2016-11-30
CL2015000354A1 (es) 2015-10-23
SG11201500900YA (en) 2015-03-30
ZA201500625B (en) 2016-08-31
CN104583198A (zh) 2015-04-29
CR20150073A (es) 2015-03-13
EA201590363A1 (ru) 2015-06-30
US9409882B2 (en) 2016-08-09
MA37893A1 (fr) 2017-08-31
IN2015DN00962A (es) 2015-06-12
JP2015530997A (ja) 2015-10-29
AU2013305102A1 (en) 2015-02-12
PE20150995A1 (es) 2015-06-29
EP2888244A1 (en) 2015-07-01
IL237128A0 (en) 2015-03-31

Similar Documents

Publication Publication Date Title
AR092269A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR106053A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
AR100006A1 (es) Derivados de tubulisina
AR090590A1 (es) COMPUESTOS 1,3,4-OXADIAZOL Y 1,3,4-TIADIAZOL COMO INHIBIDORES DE b-LACTAMASA
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR089768A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
MD20140002A2 (ro) Indazoli
AR103251A1 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR089550A1 (es) Compuestos quimicos
AR094911A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃
AR087668A1 (es) Derivados de oxazina y su uso en el tratamiento de enfermedades
AR090474A1 (es) Compuestos de tetrahidropirrolotiazina
AR089781A1 (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
AR090587A1 (es) Compuestos triciclicos sustituidos con actividad hacia los receptores ep1
AR098522A1 (es) Compuesto de triazolo-piridina
AR096153A1 (es) Derivados de pirrolo[2,3-d]pirimidina
AR097866A1 (es) Derivados de 4-azaindol
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
AR094553A1 (es) Formas de oxadiazolpirazina
AR079050A1 (es) Compuestos benzoimidazolicos y sus usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure